Ten Biological
Systems.
One Structured Framework.

Every AXIONOVA unit is catalogued inside one of ten functional systems. The taxonomy spans tissue repair, metabolic regulation, cellular renewal, growth-hormone signaling, neurocognitive function, immune defense, mitochondrial support, small-molecule modulation, endocrine regulation, and advanced weight-loss research.

The system framework gives practitioners a precise way to evaluate mechanism, protocol fit, pathway overlap, and monitoring requirements. Every system connects compound identity, dose format, documentation, and ALETHRA certification inside one governed structure.

Biological Systems
10
Verified Compounds
30
Active Catalog SKUs
26
Certification
ALETHRA

AXIONOVA uses two distinct intelligence layers. ALETHRA is the active governance layer behind identity, verification, authorization, protocol compliance, chain-of-custody, cartridge records, and device event logs across compounds, AXIS, SENSE, and partner access. ALETHA is the active AXIONOVA AI agent for coaching, protocol personalization, diet programming, guided education, practitioner support, and 24/7 user assistance. Governance and intelligence operate together. ALETHRA governs the system. ALETHA guides the experience.

RPSystem 01 / 10

Repair / Recovery

Tissue integrity, inflammatory balance, angiogenesis, and connective-tissue remodeling research.

Primary Pathway
Tissue Repair
Tissue Targets
Tendon · Gut · Skin
Protocol Window
4 – 12 weeks

The Repair / Recovery system focuses on tissue integrity, inflammatory balance, angiogenesis, and connective-tissue remodeling. Compounds in this class are evaluated for research involving fibroblast activity, soft-tissue recovery, gut-barrier context, skin repair, and post-stress structural support.

M01Fibroblast proliferation
M02VEGF-mediated angiogenesis
M03Anti-inflammatory cascade
M04Connective-tissue remodeling
RPBPC-157
BPC-157
Repair Signal
5 mg · Synthetic Peptide
ALETHRA
RPTB-500
TB-500
Tissue Repair
5 mg · Synthetic Peptide
ALETHRA
RPGHK-Cu
GHK-Cu
Skin / Repair
50 mg · Copper Tripeptide
ALETHRA
RPKPV
KPV
Anti-Inflammatory
5 mg · Tripeptide
ALETHRA
RPBPC + TB Blend
BPC + TB Blend
Repair Stack
10 mg · Compound Blend
ALETHRA
View RP Compounds 05 Verified Units · ALETHRA Certified
MTSystem 02 / 10

Metabolic / Body Composition

Lipolytic signaling, energy partitioning, hepatic fat metabolism, and insulin-pathway support.

Primary Pathway
Lipolysis
Tissue Targets
Adipose · Liver
Protocol Window
8 – 12 weeks

The Metabolic / Body Composition system addresses lipolytic signaling, energy partitioning, hepatic fat metabolism, and insulin-pathway support. It is designed for research protocols focused on body-composition change, metabolic flexibility, and adipose-tissue signaling.

M01Beta-3 adrenergic signaling
M02Lipolytic cascade activation
M03Insulin-pathway sparing
M04Hepatic fat metabolism
MTAOD-9604
AOD-9604
Lipolysis
5 mg · Peptide Fragment
ALETHRA
MTFragment 176-191
Fragment 176-191
Fat Metabolism
5 mg · Peptide Fragment
ALETHRA
View MT Compounds 02 Verified Units · ALETHRA Certified
RGSystem 03 / 10

Regenerative / Longevity

Cellular renewal, telomere biology, senescence research, and long-range healthspan signaling.

Primary Pathway
Cellular Renewal
Tissue Targets
Systemic
Protocol Window
Cyclical · 20 days

The Regenerative / Longevity system focuses on cellular renewal, telomere biology, senescence research, pineal-axis support, and long-range healthspan signaling. It is structured for protocols that require careful timing, cyclical use, and documented pathway rationale.

M01Telomerase modulation
M02Senolytic clearance
M03Pineal axis support
M04FOXO4-p53 pathway
RGEpitalon
Epitalon
Telomere Support
10 mg · Tetrapeptide
ALETHRA
RGFOXO4-DRI
FOXO4-DRI
Senolytic
5 mg · Senolytic Peptide
ALETHRA
RGGHK-Cu / TB Blend
GHK-Cu / TB Blend
Regen Stack
15 mg · Compound Blend
ALETHRA
View RG Compounds 03 Verified Units · ALETHRA Certified
GHSystem 04 / 10

Signal / GH Axis

Endogenous GH pathway support, pulsatile release architecture, and IGF-1 signaling research.

Primary Pathway
GH / IGF-1
Tissue Targets
Systemic
Protocol Window
8 – 16 weeks

The Signal / GH Axis system evaluates endogenous growth-hormone pathway support, pulsatile release architecture, IGF-1 context, and recovery signaling. It is positioned for practitioners studying signal-axis modulation rather than exogenous hormone replacement.

M01GHRH receptor agonism
M02Pulsatile GH release
M03IGF-1 axis support
M04Pituitary preservation
GHCJC-1295
CJC-1295
GH Axis
5 mg · GHRH Analog
ALETHRA
GHIpamorelin
Ipamorelin
Pulsatile GH
5 mg · Pentapeptide
ALETHRA
GHSermorelin
Sermorelin
Endogenous GH
5 mg · GHRH Peptide
ALETHRA
GHIGF-1 LR3
IGF-1 LR3
Anabolic Signal
1 mg · Analog
ALETHRA
GHCJC / Ipamorelin
CJC / Ipamorelin
GH Stack
5 mg · Compound Blend
ALETHRA
View GH Compounds 05 Verified Units · ALETHRA Certified
NCSystem 05 / 10

Neuro / Cognitive

BDNF signaling, synaptic plasticity, memory consolidation, and adaptive neurological resilience.

Primary Pathway
BDNF / Synaptic
Tissue Targets
CNS
Protocol Window
4 – 12 weeks

The Neuro / Cognitive system focuses on BDNF signaling, synaptic plasticity, dopaminergic and serotonergic modulation, memory consolidation, attention, and adaptive neurological resilience. It supports structured research into cognitive performance and neuroplasticity.

M01BDNF upregulation
M02Synaptogenesis
M03Dopaminergic modulation
M04Hippocampal neurogenesis
NCSemax
Semax
Neuro Focus
5 mg · Heptapeptide
ALETHRA
NCSelank
Selank
Anxiolytic
5 mg · Heptapeptide
ALETHRA
NCNoopept
Noopept
Cognitive
20 mg · Small Molecule
ALETHRA
NCDihexa
Dihexa
Synaptogenic
10 mg · Hexapeptide
ALETHRA
NCNSI-189
NSI-189
Neurogenesis
20 mg · Small Molecule
ALETHRA
View NC Compounds 05 Verified Units · ALETHRA Certified
IMSystem 06 / 10

Immune / Defense

T-cell activity, antimicrobial response, Th1 / Th2 balance, and macrophage activation research.

Primary Pathway
Immune Modulation
Tissue Targets
Thymus · Lymph
Protocol Window
4 – 8 weeks

The Immune / Defense system addresses T-cell activity, antimicrobial response, Th1 / Th2 balance, macrophage activation, and immune-modulation research. It is designed for protocols requiring controlled review of immune signaling and inflammatory context.

M01T-cell maturation
M02Antimicrobial activity
M03Th1 / Th2 balance
M04Macrophage activation
IMThymosin α-1
Thymosin α-1
Immune Modulator
5 mg · Polypeptide
ALETHRA
IMLL-37
LL-37
Antimicrobial
5 mg · Cathelicidin
ALETHRA
View IM Compounds 02 Verified Units · ALETHRA Certified
ACSystem 07 / 10

Mitochondrial / Cellular

Cardiolipin support, ATP production, mitochondrial biogenesis, and bioenergetic resilience.

Primary Pathway
ATP / Cardiolipin
Tissue Targets
Cardiac · Muscle
Protocol Window
8 – 12 weeks

The Mitochondrial / Cellular system focuses on cardiolipin support, ATP production, mitochondrial biogenesis, oxidative-stress reduction, and cellular energy context. It is used where protocol design depends on bioenergetic resilience and cellular efficiency.

M01Cardiolipin protection
M02ATP synthesis support
M03Mitochondrial biogenesis
M04Oxidative-stress reduction
ACMOTS-c
MOTS-c
Mitochondrial
10 mg · Mitochondrial Peptide
ALETHRA
ACSS-31
SS-31
Cardiolipin
5 mg · Mitochondrial Peptide
ALETHRA
View AC Compounds 02 Verified Units · ALETHRA Certified
SMSystem 08 / 10

Small Molecule / Modulation

Targeted enzyme and receptor-pathway research with oral bioavailability considerations.

Primary Pathway
Enzyme Modulation
Tissue Targets
Adipose · Muscle
Protocol Window
8 – 12 weeks

The Small Molecule / Modulation system covers targeted enzyme and receptor-pathway research, including NNMT inhibition, ERR-alpha agonism, NAD+ pathway support, and oral bioavailability considerations. It gives practitioners a controlled category for small-molecule interventions.

M01NNMT inhibition
M02ERR-α agonism
M03NAD+ pathway support
M04Oral bioavailability
SM5-Amino-1MQ
5-Amino-1MQ
NNMT Inhibitor
20 mg · Small Molecule
ALETHRA
SMSLU-PP-332
SLU-PP-332
Mitochondrial Mod
10 mg · ERR Agonist
ALETHRA
View SM Compounds 02 Verified Units · ALETHRA Certified
ERSystem 09 / 10

Endocrine Regulation

HPG-axis signaling, kisspeptin activity, melanocortin activation, and endocrine architecture.

Primary Pathway
HPG Axis
Tissue Targets
Hypothalamus
Protocol Window
4 – 12 weeks

The Endocrine Regulation system focuses on HPG-axis signaling, kisspeptin activity, GnRH context, melanocortin activation, and LH / FSH pathway research. It is structured for protocols involving endocrine architecture and reproductive signaling.

M01Kisspeptin signaling
M02GnRH activation
M03Melanocortin agonism
M04LH / FSH support
ERKisspeptin-10
Kisspeptin-10
HPG Axis
5 mg · Decapeptide
ALETHRA
ERPT-141
PT-141
Sexual Function
10 mg · Melanocortin
ALETHRA
View ER Compounds 02 Verified Units · ALETHRA Certified
WLSystem 10 / 10

Advanced Weight Loss

Incretin signaling, glucagon receptor activity, appetite regulation, and visceral-fat research.

Primary Pathway
Incretin / GHRH
Tissue Targets
Adipose · GI
Protocol Window
12 – 24 weeks

The Advanced Weight Loss system focuses on incretin signaling, glucagon receptor activity, appetite regulation, visceral-fat research, and body-composition protocols. It is designed for practitioner-supervised metabolic research under restricted access.

M01GLP-1 agonism
M02GIP modulation
M03Glucagon receptor
M04Visceral fat reduction
WLRetatrutide
Retatrutide
Fat Loss Driver
10 mg · Triple Agonist
ALETHRA
WLTesamorelin
Tesamorelin
Visceral Fat
5 mg · GHRH Analog
ALETHRA
View WL Compounds 02 Verified Units · ALETHRA Certified
— Begin Protocol —

Build the protocol
from the system outward.

Start with a defined biological objective, review the relevant system, confirm compound identity, and proceed through practitioner access. AXIONOVA systems are built for structured research review, not consumer self-selection.